US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Monkeypox Concept

1,516.82

+25.931.74%

Number of Gainers:9

Number of Losers:2

Number of Flat:- -

PE:- -

High:1,520.50

Open:1,490.89

Low:1,490.89

Close:1,490.89

Loading ...

Gilead's CAR-T cell therapy shows promise in deadly brain cancer

Gilead Sciences Unveils Promising Phase 3 Results: Trodelvy Plus Keytruda Reduces Disease Progression Risk by 35% in Metastatic Triple-Negative Breast Cancer

Keytruda® (Pembrolizumab) Plus Trodelvy® (Sacituzumab Govitecan-Hziy) Reduced Risk of Disease Progression or Death by 35% Versus Keytruda Plus Chemotherapy in First-Line Pd-L1+ Metastatic Triple-Negative Breast Cancer (Tnbc)

THOMSON REUTERS

Applied DNA Sciences trading halted, news pending

Emergent BioSolutions Faces Derivative Litigation Over Alleged Breaches of Fiduciary Duty and Regulatory Failures

E-Home Household Service Holdings Ltd trading halted, news pending

Applied DNA Sciences Announces 1-for-15 Reverse Stock Split Effective June 2, 2025

Director Keith Katkin Reports Disposal of Common Shares of Emergent BioSolutions Inc

Quest Diagnostics management to meet with Oppenheimer

E-Home Household Service Holdings Ltd - Board Sets Share Consolidation Ratio at 1-for-50

THOMSON REUTERS

E-Home Household Service Holdings Ltd. Announces 1-for-50 Share Consolidation to Begin Trading on Post-Split Basis

Bronstein, Gewirtz & Grossman announces class action lawsuit against Viatris

Viatris Announces Launch of First Clozapine Orally Disintegrating Tablet (Odt) in Canada

THOMSON REUTERS

Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split Effective May 23, 2025

Emergent BioSolutions Faces Multiple Lawsuits Over Securities Fraud and Manufacturing Failures

Gilead Sciences Inc. Chief Commercial Officer Johanna Mercier Reports Disposal of Common Shares

Viatris' HIV-1 Generic Medicine Gets Backing From European Medicines Agency

MT Newswires Live

Gilead Sciences Says Trodelvy Met Primary Endpoint in Phase 3 Breast Cancer Trial

MT Newswires Live

BRIEF-ASCENT-03 - Trodelvy Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for Checkpoint Inhibitors

Gilead announces ASCENT-03 study meets primary endpoint

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK4583/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4583","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4583\",,,,,undefined,":{"symbol":"BK4583","market":"US","secType":"PLATE","nameCN":"Monkeypox Concept","latestPrice":1516.8202,"timestamp":1749239999999,"preClose":1490.8878,"halted":0,"volume":19417802,"delay":0,"changeRate":0.017394,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":25.932373,"latestTime":"06-06 16:00:00 EDT","open":1490.8905,"high":1520.5037,"low":1490.8905,"amount":791036545.199207,"amplitude":0.019863,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1749254400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":3.888099,"peRate":61.301568,"turnoverRate":0.00723,"increases":9,"decrements":2,"flats":0,"marketCap":170778104380.5,"floatMarketCap":170112410423},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4583\",,,,,undefined,":{"symbol":"BK4583","high":1520.5037,"amplitude":0.019863,"preClose":1490.8878,"low":1490.8905,"pbRate":"3.888099","latestPrice":1516.8202,"volume":19417802,"delay":0,"open":1490.8905,"prevYearClose":1284.7982,"prevWeekClose":1489.9341,"prevMonthClose":1489.9341,"prevQuarterClose":1502.9401,"fiveDayClose":1489.9341,"twentyDayClose":1362.5507,"sixtyDayClose":1528.2911,"secType":"PLATE","market":"US","turnoverRate":0.00723,"peRate":61.301568,"marketCap":170778104380.5,"floatMarketCap":170112410423,"timestamp":1749239999999,"nameCN":"Monkeypox Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4583\",,,,undefined,":{"bkCode":"BK4583","up":9,"down":2,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4583\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2540731283","title":"Gilead's CAR-T cell therapy shows promise in deadly brain cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2540731283","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540731283?lang=en_us&edition=fundamental","pubTime":"2025-06-01 20:00","pubTimestamp":1748779200,"startTime":"0","endTime":"0","summary":"Gilead's CAR-T cell therapy shows promise in deadly brain cancerTherapy shrank tumors in 62% of patients in small trialResult was not lasting beyond a few months for most patients\"We're on the right t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250601:nL2N3S304Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1066051498.USD","BK4139","LU2089984988.USD","LU1674673691.USD","LU0109394709.USD","IE0002270589.USD","LU1674673428.USD","LU0058720904.USD","LU0889565916.HKD","IE00B7SZLL34.SGD","LU0289739699.SGD","IE00B3T34201.USD","LU1839511570.USD","BK4583","GILD","BK4585","LU2087621335.USD","LU2468319806.SGD","LU1571399168.USD","IE00B19Z3581.USD","IE00B19Z3B42.SGD","BK4578","IE00BKVL7J92.USD","LU0320765992.SGD","BK4566","LU0234570918.USD","BK4532","LU1430594728.SGD","LU1066053197.SGD","IE00BSNM7G36.USD","LU0823416689.USD","BK4568","LU1585245621.USD","LU1778281490.HKD","IE00BZ1G4Q59.USD","BK4550","BK4588"],"gpt_icon":0},{"id":"2539786187","title":"Gilead Sciences Unveils Promising Phase 3 Results: Trodelvy Plus Keytruda Reduces Disease Progression Risk by 35% in Metastatic Triple-Negative Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2539786187","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539786187?lang=en_us&edition=fundamental","pubTime":"2025-05-31 20:01","pubTimestamp":1748692863,"startTime":"0","endTime":"0","summary":"Gilead Sciences Unveils Promising Phase 3 Results: Trodelvy Plus Keytruda Reduces Disease Progression Risk by 35% in Metastatic Triple-Negative Breast Cancer. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences Inc. published the original content used to generate this news brief via Business Wire  on May 31, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250531:nNDL5DpLrT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GILD","LU2468319806.SGD","BK4578","LU1674673691.USD","LU2087621335.USD","LU1066051498.USD","LU0889565916.HKD","LU0289739699.SGD","BK4568","LU0058720904.USD","LU1778281490.HKD","LU1839511570.USD","BK4532","LU0234570918.USD","IE0002270589.USD","BK4566","LU1585245621.USD","LU0320765992.SGD","LU0109394709.USD","IE00B7SZLL34.SGD","LU2089984988.USD","IE00B19Z3581.USD","BK4550","BK4585","IE00B19Z3B42.SGD","LU0823416689.USD","IE00BSNM7G36.USD","IE00BZ1G4Q59.USD","BK4583","LU1571399168.USD","IE00B3T34201.USD","LU1430594728.SGD","BK4588","IE00BKVL7J92.USD","BK4139","LU1674673428.USD","LU1066053197.SGD"],"gpt_icon":0},{"id":"2539786943","title":"Keytruda® (Pembrolizumab) Plus Trodelvy® (Sacituzumab Govitecan-Hziy) Reduced Risk of Disease Progression or Death by 35% Versus Keytruda Plus Chemotherapy in First-Line Pd-L1+ Metastatic Triple-Negative Breast Cancer (Tnbc)","url":"https://stock-news.laohu8.com/highlight/detail?id=2539786943","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539786943?lang=en_us&edition=fundamental","pubTime":"2025-05-31 20:00","pubTimestamp":1748692800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250531:nTUABMKK2P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MRK","SG9999014559.SGD","LU1430594728.SGD","LU2361044949.HKD","LU1291159041.SGD","SG9999002232.USD","LU2023250843.SGD","LU0861579265.USD","GILD","LU0985320562.USD","LU0106261372.USD","BK4559","BK4588","IE00BKVL7J92.USD","BK4566","IE0002141913.USD","LU0266013472.USD","LU1571399168.USD","LU0265550946.USD","LU1023059063.AUD","IE00B19Z3B42.SGD","IE000M9KFDE8.USD","LU1066051498.USD","SG9999014575.USD","IE00BBT3K403.USD","IE00BFTCPJ56.SGD","LU0211331839.USD","SG9999013999.USD","BK4550","IE00BZ1G4Q59.USD","BK4139","LU0109394709.USD","SG9999001440.SGD","BK4583","SG9999014567.USD","LU0320765992.SGD","LU2087621335.USD","IE00BLSP4239.USD","LU1037948897.HKD","LU0289739699.SGD","BK4516","LU0234570918.USD","SG9999015358.SGD","LU0965509101.SGD","LU2361044865.SGD","LU0965508806.USD","LU1934455863.HKD","LU2023250504.SGD","LU1989771016.USD","BK4007"],"gpt_icon":0},{"id":"2539206692","title":"Applied DNA Sciences trading halted, news pending","url":"https://stock-news.laohu8.com/highlight/detail?id=2539206692","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539206692?lang=en_us&edition=fundamental","pubTime":"2025-05-31 07:50","pubTimestamp":1748649032,"startTime":"0","endTime":"0","summary":"19:50 EDT Applied DNA Sciences (APDN) trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving bre...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/applied-dna-sciences-trading-halted-news-pending-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/applied-dna-sciences-trading-halted-news-pending-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4121","DNA","APDN","BK4109","BK4583","BK4139"],"gpt_icon":0},{"id":"2539277150","title":"Emergent BioSolutions Faces Derivative Litigation Over Alleged Breaches of Fiduciary Duty and Regulatory Failures","url":"https://stock-news.laohu8.com/highlight/detail?id=2539277150","media":"Reuters","labels":["policyRegulatory","merge","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539277150?lang=en_us&edition=fundamental","pubTime":"2025-05-31 03:37","pubTimestamp":1748633852,"startTime":"0","endTime":"0","summary":"Emergent BioSolutions Inc. has reached a settlement in a series of derivative actions alleging breaches of fiduciary duty by certain current and former officers and directors. The claims centered on the company's Bayview, Maryland facility, which allegedly failed to meet regulatory standards and produce safe vaccine substances. The plaintiffs argued that Emergent's leadership did not establish adequate monitoring systems and ignored warnings, including FDA inspection reports that highlighted repeated failures in quality control and manufacturing practices. The settlement resolves these allegations, with all related claims being dismissed with prejudice. The Delaware Court had previously stayed the action pending the resolution of a related securities case.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nNDL8vGVpZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Emergent BioSolutions Faces Derivative Litigation Over Alleged Breaches of Fiduciary Duty and Regulatory Failures","news_tag":"policyRegulatory,merge,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EBS","BK4583"],"gpt_icon":0},{"id":"2539129235","title":"E-Home Household Service Holdings Ltd trading halted, news pending","url":"https://stock-news.laohu8.com/highlight/detail?id=2539129235","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539129235?lang=en_us&edition=fundamental","pubTime":"2025-05-30 07:50","pubTimestamp":1748562610,"startTime":"0","endTime":"0","summary":"19:50 EDT E-Home Household Service (EJH) Holdings Ltd trading halted, news pending Published first on TheFly – the ultimate source for real-time, m...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/e-home-household-service-holdings-ltd-trading-halted-news-pending-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/e-home-household-service-holdings-ltd-trading-halted-news-pending-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4195","BK4211","HBCP","BK4192","BK4583","BK4539","EJH"],"gpt_icon":0},{"id":"2539748257","title":"Applied DNA Sciences Announces 1-for-15 Reverse Stock Split Effective June 2, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2539748257","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539748257?lang=en_us&edition=fundamental","pubTime":"2025-05-29 20:00","pubTimestamp":1748520030,"startTime":"0","endTime":"0","summary":"Applied DNA Sciences Inc. has announced a 1-for-15 reverse stock split of its common stock, effective June 2, 2025. The company's shares will begin trading on a split-adjusted basis on Nasdaq under the symbol \"APDN\" from that date. This move is intended to help the company comply with Nasdaq's $1.00 minimum bid price requirement. The number of outstanding shares will reduce from approximately 7.8 million to about 519 thousand, with no change in the total authorized shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Applied DNA Sciences Inc. published the original content used to generate this news brief via ACCESS Newswire  on May 29, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nNDLb9Rn83:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APDN","BK4121","BK4583"],"gpt_icon":0},{"id":"2539060164","title":"Director Keith Katkin Reports Disposal of Common Shares of Emergent BioSolutions Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2539060164","media":"Reuters","labels":["shareholding","merge","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539060164?lang=en_us&edition=fundamental","pubTime":"2025-05-29 04:09","pubTimestamp":1748462940,"startTime":"0","endTime":"0","summary":"Keith Katkin, a Director, reported a disposal of common shares of Emergent BioSolutions Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Emergent BioSolutions Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 28, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nNDLc8TSsP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Director Keith Katkin Reports Disposal of Common Shares of Emergent BioSolutions Inc","news_tag":"shareholding,merge,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","EBS","BK4139"],"gpt_icon":0},{"id":"2538397412","title":"Quest Diagnostics management to meet with Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2538397412","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538397412?lang=en_us&edition=fundamental","pubTime":"2025-05-28 10:20","pubTimestamp":1748398808,"startTime":"0","endTime":"0","summary":"Meeting to be held on May 28 hosted by Oppenheimer. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/quest-diagnostics-management-to-meet-with-oppenheimer-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/quest-diagnostics-management-to-meet-with-oppenheimer-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4127","BK4588","BK4583","BK4196","BK4567","LU1854103824.USD","LU1854104046.USD","DGX","OPY","BK4585"],"gpt_icon":0},{"id":"2538648494","title":"E-Home Household Service Holdings Ltd - Board Sets Share Consolidation Ratio at 1-for-50","url":"https://stock-news.laohu8.com/highlight/detail?id=2538648494","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538648494?lang=en_us&edition=fundamental","pubTime":"2025-05-28 04:31","pubTimestamp":1748377862,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250527:nFWN3RZ148:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","EJH","BK4192","BK4583"],"gpt_icon":0},{"id":"2538494508","title":"E-Home Household Service Holdings Ltd. Announces 1-for-50 Share Consolidation to Begin Trading on Post-Split Basis","url":"https://stock-news.laohu8.com/highlight/detail?id=2538494508","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538494508?lang=en_us&edition=fundamental","pubTime":"2025-05-28 04:30","pubTimestamp":1748377835,"startTime":"0","endTime":"0","summary":"E-Home Household Service Holdings Ltd.  announced a share consolidation, approved on May 1, 2025, at a one-for-fifty ratio, effective May 30, 2025. This move, aimed at meeting Nasdaq's minimum bid price rule, reduces the pre-split 183.7 million shares to approximately 3.67 million post-split. The new CUSIP number is G2952X153. The consolidation maintains shareholders' proportional voting power and ownership interest.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. E-Home Household Service Holdings Ltd. published the original content used to generate this news brief via PR Newswire  on May 27, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250527:nNDL65Ymbx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EJH","BK4539","BK4192","BK4583"],"gpt_icon":0},{"id":"2538546301","title":"Bronstein, Gewirtz & Grossman announces class action lawsuit against Viatris","url":"https://stock-news.laohu8.com/highlight/detail?id=2538546301","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538546301?lang=en_us&edition=fundamental","pubTime":"2025-05-27 19:30","pubTimestamp":1748345455,"startTime":"0","endTime":"0","summary":"Bronstein, Gewirtz & Grossman notifies investors that a class action lawsuit has been filed against Viatris (VTRS) and certain of its officers. Thi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bronstein-gewirtz-grossman-announces-class-action-lawsuit-against-viatris-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bronstein-gewirtz-grossman-announces-class-action-lawsuit-against-viatris-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1839511570.USD","BK4588","BK4583","BK4585","BK4007","LU2087621335.USD","VTRS"],"gpt_icon":0},{"id":"2538468673","title":"Viatris Announces Launch of First Clozapine Orally Disintegrating Tablet (Odt) in Canada","url":"https://stock-news.laohu8.com/highlight/detail?id=2538468673","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538468673?lang=en_us&edition=fundamental","pubTime":"2025-05-27 18:59","pubTimestamp":1748343547,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250527:nFWN3RY0WY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","BK4585","LU2087621335.USD","VTRS","LU1839511570.USD","BK4007","BK4583"],"gpt_icon":0},{"id":"2537617157","title":"Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split Effective May 23, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2537617157","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537617157?lang=en_us&edition=fundamental","pubTime":"2025-05-24 05:10","pubTimestamp":1748034638,"startTime":"0","endTime":"0","summary":"Aptevo Therapeutics Inc. announced amendments to its bylaws to effect a reverse stock split at a 1-for-20 ratio. This change, approved by the Board on May 21, 2025, was filed and became effective on May 23, 2025. The company's stock will trade on a split-adjusted basis on Nasdaq starting May 27, 2025. No fractional shares will be issued.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptevo Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 23, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250523:nNDLGM8xD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","BK4139","APVO","EBS"],"gpt_icon":0},{"id":"2537239154","title":"Emergent BioSolutions Faces Multiple Lawsuits Over Securities Fraud and Manufacturing Failures","url":"https://stock-news.laohu8.com/highlight/detail?id=2537239154","media":"Reuters","labels":["policyRegulatory","merge","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537239154?lang=en_us&edition=fundamental","pubTime":"2025-05-24 04:07","pubTimestamp":1748030843,"startTime":"0","endTime":"0","summary":"Emergent BioSolutions Inc. is currently embroiled in significant litigation following allegations of securities fraud and manufacturing failures. The company faced class action claims from stockholders in the case In re Emergent BioSolutions Inc. Securities Litigation, filed in April 2021. Additionally, in June 2021, the Lincolnshire Police Pension Fund filed a derivative complaint against certain directors and officers of Emergent, followed by a similar complaint in August 2021. The litigation centers around extensive vaccine manufacturing failures as reported by House Committees in May 2022, and related efforts to conceal these deficiencies. Settlement negotiations are ongoing, with mediation efforts taking place in early 2024. The outcome of these legal proceedings could have significant implications for Emergent's operations and reputation.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250523:nNDL3RJMcR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"Emergent BioSolutions Faces Multiple Lawsuits Over Securities Fraud and Manufacturing Failures","news_tag":"policyRegulatory,merge,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4583","EBS"],"gpt_icon":0},{"id":"2537715197","title":"Gilead Sciences Inc. Chief Commercial Officer Johanna Mercier Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2537715197","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537715197?lang=en_us&edition=fundamental","pubTime":"2025-05-24 03:17","pubTimestamp":1748027827,"startTime":"0","endTime":"0","summary":"Johanna Mercier, Chief Commercial Officer of Gilead Sciences Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 23, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250523:nNDL7f4HdK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Gilead Sciences Inc. Chief Commercial Officer Johanna Mercier Reports Disposal of Common Shares","news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","LU1585245621.USD","LU2087621335.USD","IE00B19Z3B42.SGD","LU2089984988.USD","IE00BKVL7J92.USD","LU0889565916.HKD","LU1674673428.USD","BK4585","IE00BSNM7G36.USD","LU0320765992.SGD","IE0002270589.USD","LU1778281490.HKD","LU2468319806.SGD","LU0109394709.USD","BK4532","BK4578","LU1066051498.USD","LU0289739699.SGD","BK4588","IE00B7SZLL34.SGD","BK4566","BK4550","GILD","IE00B3T34201.USD","LU0058720904.USD","IE00BZ1G4Q59.USD","LU1066053197.SGD","LU0823416689.USD","LU1839511570.USD","BK4568","LU1674673691.USD","IE00B19Z3581.USD","LU1430594728.SGD","LU1571399168.USD","LU0234570918.USD","BK4139"],"gpt_icon":0},{"id":"2537713412","title":"Viatris' HIV-1 Generic Medicine Gets Backing From European Medicines Agency","url":"https://stock-news.laohu8.com/highlight/detail?id=2537713412","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537713412?lang=en_us&edition=fundamental","pubTime":"2025-05-23 21:30","pubTimestamp":1748007027,"startTime":"0","endTime":"0","summary":"The European Medicines Agency's Committee for Medicinal Products for Human Use said Friday it's recommending a marketing authorization for Viatris' (VTRS) emtricitabine/tenofovir alafenamide to treat ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","LU2087621335.USD","MDCO","LU1839511570.USD","BK4583","BK4588","BK4585","VTRS"],"gpt_icon":0},{"id":"2537131674","title":"Gilead Sciences Says Trodelvy Met Primary Endpoint in Phase 3 Breast Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2537131674","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537131674?lang=en_us&edition=fundamental","pubTime":"2025-05-23 21:00","pubTimestamp":1748005217,"startTime":"0","endTime":"0","summary":"Gilead Sciences  said Friday that its experimental drug, trodelvy, met the primary endpoint in a phase 3 trial, showing a statistically significant and clinically meaningful improvement in progression-free survival over chemotherapy in patients with a type of breast cancer who are not candidates for immunotherapy.The company said the drug's safety profile in the study was consistent with previous trials, with no new safety signals observed.The drugmaker said overall survival, a key secondary endpoint, was not yet mature at the time of analysis, and further monitoring is underway.Gilead said it is also evaluating trodelvy in multiple ongoing phase 3 studies across various tumor types, including HER2-negative breast cancer, lung, and gynecologic cancers.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GILD","IE0002270589.USD","LU0234570918.USD","IE00B19Z3581.USD","BK4566","BK4550","LU0823416689.USD","LU0058720904.USD","LU1778281490.HKD","LU1571399168.USD","LU2087621335.USD","LU1066051498.USD","LU1430594728.SGD","LU0289739699.SGD","LU1674673428.USD","IE00BKVL7J92.USD","LU0889565916.HKD","LU1674673691.USD","BK4585","BK4568","BK4583","LU0320765992.SGD","LU2468319806.SGD","BK4532","IE00BSNM7G36.USD","IE00B3T34201.USD","LU0109394709.USD","BK4139","IE00B7SZLL34.SGD","LU1839511570.USD","LU2089984988.USD","IE00B19Z3B42.SGD","LU1066053197.SGD","IE00BZ1G4Q59.USD","BK4588","BK4578","LU1585245621.USD"],"gpt_icon":0},{"id":"2537318971","title":"BRIEF-ASCENT-03 - Trodelvy Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for Checkpoint Inhibitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2537318971","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537318971?lang=en_us&edition=fundamental","pubTime":"2025-05-23 20:49","pubTimestamp":1748004563,"startTime":"0","endTime":"0","summary":"BRIEF-ASCENT-03 - Trodelvy Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250523:nTUABJLBB8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1066051498.USD","LU0320765992.SGD","IE00BZ1G4Q59.USD","BK4583","BK4585","LU0058720904.USD","IE00BKVL7J92.USD","LU0289739699.SGD","LU1778281490.HKD","BK4550","LU1066053197.SGD","IE0002270589.USD","IE00B19Z3B42.SGD","IE00B3T34201.USD","LU1430594728.SGD","IE00B7SZLL34.SGD","LU0109394709.USD","BK4578","GILD","LU1674673691.USD","LU1839511570.USD","BK4532","BK4566","LU1585245621.USD","IE00B19Z3581.USD","LU1571399168.USD","LU2087621335.USD","BK4588","LU2468319806.SGD","LU0889565916.HKD","LU2089984988.USD","LU0823416689.USD","LU0234570918.USD","IE00BSNM7G36.USD","BK4568","BK4139","LU1674673428.USD"],"gpt_icon":0},{"id":"2537813975","title":"Gilead announces ASCENT-03 study meets primary endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2537813975","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537813975?lang=en_us&edition=fundamental","pubTime":"2025-05-23 20:40","pubTimestamp":1748004013,"startTime":"0","endTime":"0","summary":"Gilead (GILD) announced topline results from the Phase 3 ASCENT-03 study of Trodelvy. The study met its primary endpoint, demonstrating a highly st...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gilead-announces-ascent-03-study-meets-primary-endpoint-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gilead-announces-ascent-03-study-meets-primary-endpoint-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B7SZLL34.SGD","LU2468319806.SGD","IE0002270589.USD","LU0109394709.USD","BK4532","LU0234570918.USD","LU1571399168.USD","IE00B19Z3581.USD","BK4588","LU0889565916.HKD","IE00B19Z3B42.SGD","BK4566","BK4578","LU1674673428.USD","BK4550","LU0289739699.SGD","BK4139","BK4583","LU2089984988.USD","LU1674673691.USD","LU1585245621.USD","LU0823416689.USD","LU2087621335.USD","GILD","IE00BZ1G4Q59.USD","LU1839511570.USD","LU0320765992.SGD","LU0058720904.USD","IE00BKVL7J92.USD","BK4585","LU1430594728.SGD","LU1066051498.USD","IE00B3T34201.USD","LU1778281490.HKD","IE00BSNM7G36.USD","LU1066053197.SGD","BK4568"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":47,"code":"91000000","status":"200"}]}}